CONFLICTS OF INTEREST:
No potential competing interest was declared by the authors
  1. Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 Aug 25; 4(16): 4020–4027.
  2. Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plazmasitoid dendritic cell neoplasm (BPDCN), N. Engl J Med.379(2018)1479-1482.
  3. DiNardo CD, Pratz K, Pullarkart V et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood. 2019 Jan 3; 133(1): 7–17.
  4. Arber AD, Orazzi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood (2016) 127 (20): 2391–2405
  5. Jegalian AG, Buxbaum MP, Facchetti F et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010;95(11):1873-9.
  6. Li Y, Sun V, Sun W et al. Blastic plasmacytoid dendritic cell neoplasm in children. Hematol Oncol Clin N AM 34(2020)601-612.
  7. Sakashita K, Saito S, Yanagisawa R et al. Usefulness of allogeneic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: A case report and review of literature. Pediatr Blood Cancer 2013;60(11):E140-2.
  8. Beziat G, Ysebaert L. Tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm(BPDCN): A brief report on emerging data. Oncotargets and Therapy (2020):13;5199-5205.
  9. Beziat G, Ysebaert L., Gaudin C et al. venetoclax to treat blastic plasmacytoid dendritic cell neoplasm: A case-report and a review of literature. Leukemia Research 85(2019)106199.
  10. Piccini M, Loscocco GG, Gianfaldoni G et al. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology (2020) 99:907–909.